vs
Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
CARRIAGE SERVICES INC is the larger business by last-quarter revenue ($105.5M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 8.0%). CARRIAGE SERVICES INC produced more free cash flow last quarter ($6.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 1.0%).
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CSV vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $86.8M |
| Net Profit | $12.3M | — |
| Gross Margin | 34.8% | 67.4% |
| Operating Margin | 23.3% | -84.7% |
| Net Margin | 11.6% | — |
| Revenue YoY | 8.0% | 17.7% |
| Net Profit YoY | 24.5% | — |
| EPS (diluted) | $0.76 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.5M | $86.8M | ||
| Q3 25 | $102.7M | $67.5M | ||
| Q2 25 | $102.1M | $60.0M | ||
| Q1 25 | $107.1M | $49.3M | ||
| Q4 24 | $97.7M | $73.7M | ||
| Q3 24 | $100.7M | $58.6M | ||
| Q2 24 | $102.3M | $31.1M | ||
| Q1 24 | $103.5M | $715.0K |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $-91.3M | ||
| Q2 25 | $11.7M | $-111.7M | ||
| Q1 25 | $20.9M | $-116.2M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.9M | $-83.5M | ||
| Q2 24 | $6.3M | $-97.1M | ||
| Q1 24 | $7.0M | $-113.0M |
| Q4 25 | 34.8% | 67.4% | ||
| Q3 25 | 35.3% | 43.0% | ||
| Q2 25 | 35.2% | 5.5% | ||
| Q1 25 | 35.3% | -0.8% | ||
| Q4 24 | 34.4% | 68.7% | ||
| Q3 24 | 35.2% | 46.2% | ||
| Q2 24 | 36.2% | -0.8% | ||
| Q1 24 | 36.0% | — |
| Q4 25 | 23.3% | -84.7% | ||
| Q3 25 | 17.0% | -140.7% | ||
| Q2 25 | 23.5% | -189.8% | ||
| Q1 25 | 29.5% | -245.8% | ||
| Q4 24 | 21.6% | -117.5% | ||
| Q3 24 | 22.7% | -152.1% | ||
| Q2 24 | 18.0% | -327.6% | ||
| Q1 24 | 18.8% | -16464.6% |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | -135.3% | ||
| Q2 25 | 11.5% | -186.2% | ||
| Q1 25 | 19.5% | -235.5% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 9.8% | -142.7% | ||
| Q2 24 | 6.1% | -312.2% | ||
| Q1 24 | 6.7% | -15800.8% |
| Q4 25 | $0.76 | — | ||
| Q3 25 | $0.41 | — | ||
| Q2 25 | $0.74 | $-0.33 | ||
| Q1 25 | $1.34 | $-0.36 | ||
| Q4 24 | $0.62 | $-0.24 | ||
| Q3 24 | $0.63 | $-0.28 | ||
| Q2 24 | $0.40 | $-0.34 | ||
| Q1 24 | $0.45 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.8M | $698.6M |
| Total Assets | $1.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $297.0M | ||
| Q3 25 | $1.2M | $300.8M | ||
| Q2 25 | $1.4M | $301.2M | ||
| Q1 25 | $4.6M | $359.7M | ||
| Q4 24 | $1.2M | $323.8M | ||
| Q3 24 | $1.3M | $397.5M | ||
| Q2 24 | $1.5M | $412.5M | ||
| Q1 24 | $1.7M | $356.2M |
| Q4 25 | $254.8M | $698.6M | ||
| Q3 25 | $242.1M | $702.3M | ||
| Q2 25 | $235.4M | $698.5M | ||
| Q1 25 | $223.1M | $767.9M | ||
| Q4 24 | $208.6M | $710.4M | ||
| Q3 24 | $198.1M | $773.5M | ||
| Q2 24 | $187.9M | $768.5M | ||
| Q1 24 | $179.6M | $680.0M |
| Q4 25 | $1.3B | $913.2M | ||
| Q3 25 | $1.3B | $904.9M | ||
| Q2 25 | $1.3B | $907.4M | ||
| Q1 25 | $1.3B | $966.7M | ||
| Q4 24 | $1.3B | $910.4M | ||
| Q3 24 | $1.3B | $991.1M | ||
| Q2 24 | $1.3B | $964.3M | ||
| Q1 24 | $1.3B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | $-52.6M |
| Free Cash FlowOCF − Capex | $6.2M | $-61.9M |
| FCF MarginFCF / Revenue | 5.9% | -71.3% |
| Capex IntensityCapex / Revenue | 7.5% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.1M | $-52.6M | ||
| Q3 25 | $24.7M | $-78.7M | ||
| Q2 25 | $8.1M | $-67.4M | ||
| Q1 25 | $13.8M | $-103.7M | ||
| Q4 24 | $9.3M | $-73.3M | ||
| Q3 24 | $20.9M | $-59.0M | ||
| Q2 24 | $2.2M | $-98.4M | ||
| Q1 24 | $19.7M | $-122.3M |
| Q4 25 | $6.2M | $-61.9M | ||
| Q3 25 | $18.0M | $-89.5M | ||
| Q2 25 | $5.2M | $-74.9M | ||
| Q1 25 | $10.6M | $-109.9M | ||
| Q4 24 | $4.9M | $-77.5M | ||
| Q3 24 | $16.2M | $-61.3M | ||
| Q2 24 | $-1.4M | $-98.9M | ||
| Q1 24 | $16.2M | $-126.5M |
| Q4 25 | 5.9% | -71.3% | ||
| Q3 25 | 17.5% | -132.7% | ||
| Q2 25 | 5.1% | -124.9% | ||
| Q1 25 | 9.9% | -222.8% | ||
| Q4 24 | 5.0% | -105.1% | ||
| Q3 24 | 16.1% | -104.6% | ||
| Q2 24 | -1.4% | -317.9% | ||
| Q1 24 | 15.6% | -17685.3% |
| Q4 25 | 7.5% | 10.7% | ||
| Q3 25 | 6.5% | 16.1% | ||
| Q2 25 | 2.8% | 12.4% | ||
| Q1 25 | 3.0% | 12.6% | ||
| Q4 24 | 4.5% | 5.7% | ||
| Q3 24 | 4.6% | 3.9% | ||
| Q2 24 | 3.5% | 1.4% | ||
| Q1 24 | 3.4% | 583.4% |
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 2.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
